The LEADER trial assessed the CV safety of liraglutide versus placebo in >9000 patients with T2D who had established CV disease or were aged ≥60 years with ≥1 CV risk factor.2 This module details the CV outcomes, renal endpoints and safety results from the trial.

Rate this content
  • LEADER Trial
  • LEADER: study design
  • LEADER: baseline characteristics
  • LEADER: CV disease at baseline
  • LEADER: renal function at baseline
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go